Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Intra-Cellular Therapies, Inc. (ITCI)
|
Add to portfolio |
|
|
|
| Price: |
$52.02
| | Metrics |
| OS: |
96.1
|
M
| |
|
|
| Market cap: |
$5
|
B
| |
|
|
|
Net cash:
|
$538
|
M
| |
$5.60
|
per share
|
|
EV:
|
$4.46
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($323)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| Revenues | 83.8 | 22.8 | 0.1 | 0.0 | 0.2 | 0.3 | 0.1 | 0.6 |
| Revenue growth | 267.3% | 37537.1% | | -100.0% | -25.7% | 262.0% | -84.2% | -78.9% |
| Cost of goods sold | 8.0 | 1.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 75.8 | 20.9 | 0.1 | 0.0 | 0.2 | 0.3 | 0.1 | 0.6 |
| Gross margin | 90.4% | 91.7% | 100.0% | | 100.0% | 100.0% | 100.0% | 100.0% |
| Research and development | 88.8 | 65.8 | 89.1 | 132.2 | 79.4 | 93.8 | 87.7 | 21.2 |
| General and administrative | 272.6 | 186.4 | 64.9 | 30.1 | 23.7 | 24.8 | 18.2 | 10.3 |
| EBIT | -285.7 | -231.2 | -154.0 | -162.3 | -102.8 | -118.3 | -105.8 | -31.0 |
| EBIT margin | -340.9% | -1013.6% | -254090.5% | | -41832.6% | -35760.0% | -115815.9% | -5367.5% |
| Pre-tax income | -284.1 | -227.0 | -147.7 | -155.1 | -98.8 | -115.4 | -104.8 | -30.7 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | -1.1 | 1.1 | 0.0 | 0.0 |
| Tax rate | | | | | 1.1% | | | |
| Net income | -284.1 | -227.0 | -147.7 | -155.1 | -97.8 | -116.4 | -104.8 | -30.7 |
| Net margin | -339.0% | -995.1% | -243713.7% | | -39771.6% | -35205.8% | -114698.5% | -5316.4% |
| |
| Diluted EPS | ($3.50) | ($3.23) | ($2.68) | ($2.84) | ($2.12) | ($2.69) | ($2.91) | ($1.07) |
| Shares outstanding (diluted) | 81.3 | 70.4 | 55.2 | 54.7 | 46.2 | 43.2 | 36.1 | 28.7 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|